NCT00002028已完成不适用
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
Bristol-Myers Squibb2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program due to protocol exclusion or geographic location.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineLeukoencephalopathy, Progressive MultifocalHIV InfectionsNCT00002274Bristol-Myers Squibb
已完成
1 期
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant WomenPregnancyHIV InfectionsNCT00000839National Institute of Allergy and Infectious Diseases (NIAID)12
已完成
不适用
Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic ScoliosisScoliosisNCT01465295SpineForm LLC6
已完成
1 期
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related ComplexHIV InfectionsNCT00000710National Institute of Allergy and Infectious Diseases (NIAID)42
已完成
不适用
Development of Novel Therapies for NIDDMMetabolismNCT01905722Duke University64